Condition
Diarrhea Rotavirus
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
75%
3 of 4 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (2)
P 3 (1)
P 4 (1)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04658914Phase 2Completed
Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa
NCT03703336Phase 3Completed
Phase III Study of Liquid Formulation of ROTAVIN
NCT03602053Phase 2Completed
Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia
NCT02286895Phase 4CompletedPrimary
Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali
Showing all 4 trials